中国肛肠病杂志2025，Vol.45Issue(12)：1-6,6.
化疗联合靶向治疗对结直肠癌疗效及安全性的Meta分析
Meta-Analysis of Efficacy and Safety of Chemotherapy Combined with Targeted Therapy for Colorectal Cancer
王宇航 1刘春远1
作者信息
- 1. 滨州医学院第二临床医学院/滨州医学院烟台附属医院(山东 烟台 264100)
- 折叠
摘要
Abstract
Objective To systematically evaluate the efficacy and safety of chemotherapy combined with tar-geted therapy for patients with colorectal cancer(CRC).Methods By searching databases such as Wan-fang,CNKI,and PubMed,total 17 randomized controlled trial(RCT)studies from 2010 to 2025 were included.The Mantel-Haenszel(M-H)test was performed using RevMan 5.3 software,combined with net work Meta-analysis.Results The overall remission rate was 61.6%in the cetuximab(Cet)combined with chemotherapy group and 68.1%in the Bevacizumab(Bev)combined with chemotherapy group,both signifi-cantly higher than that in the chemotherapy-alone group(P<0.05).There were no statistically significant dif-ferences in the incidence of complications such as gastrointestinal reactions and liver and kidney function impair-ment between the two combination therapy groups and the chemotherapy-alone group(P>0.05).No obvious publication bias was found in this study.Conclusion The combination of the two targeted drugs with chemo-therapy can improve the overall remission rate of CRC patients.According to the results of network Meta-analysis,FOLFIRI+Cet and FOLFIRI+Bev regimens can significantly improve the remission rate of CRC patients with fewer complications,providing an evidence-based basis for clinical treatment.Further attention should be paid to long-term survival data and individualized treatment strategies in the future.关键词
结直肠癌/化疗/靶向治疗/Meta分析Key words
Colorectal cancer/Chemotherapy/Targeted therapy/Meta-analysis引用本文复制引用
王宇航,刘春远..化疗联合靶向治疗对结直肠癌疗效及安全性的Meta分析[J].中国肛肠病杂志,2025,45(12):1-6,6.
